Below 45% is the standard hematocrit target for PV, but symptoms can persist. This article explores when an individual target may help and the tradeoff of more phlebotomies and iron deficiency.
Do your symptoms track with your hematocrit? Has your hematologist discussed a personal target?
https://pvreporter.com/polycythemia-vera-hematocrit-targets/
What does this mean for patients? Our latest article explains the trial results, dosing, side effects, and questions to discuss with your hematologist.
Read more: https://pvreporter.com/fda-approves-besremi-for-essential-thrombocythemia-et/
In recognition of MPN Awareness Day today and Blood Cancer Awareness Month, MPN Cancer Connection is proud to share A Guide to Polycythemia Vera (PV) with our MPN community.
This free guide helps patients and caregivers understand PV, explore treatment options, and prepare for conversations with their healthcare team.
📖 Read or download your free guide: https://mpncancerconnection.org/2026/09/polycythemia-vera-guide/
Please share with someone who could benefit!
#MPNAwarenessDay #BloodCancerAwarenessMonth #PolycythemiaVera
I run PV Reporter and wrote a patient-focused breakdown covering how rusfertide works, the VERIFY trial results, phlebotomy burden, safety information, and questions to ask your hematologist.
Article: https://pvreporter.com/fda-approves-mimrylo-rusfertide-polycythemia-vera/
This is for education and discussion, not medical advice. I’d be interested to hear what questions other PV patients have about this treatment.
New Phase 2 results for divesiran could matter to people with PV who require frequent phlebotomies.
In the SANRECO trial, 88% of divesiran-treated patients kept hematocrit below 45% without phlebotomy during weeks 18 through 36, compared with 19% on placebo. The every-12-week group also showed an 81.3% response rate.
These are promising topline findings, but divesiran remains investigational. Full data and a larger Phase 3 trial are still needed.
https://pvreporter.com/divesiran-cuts-phlebotomy-need-in-phase-2-pv-trial/
New 2-year SURPASS-ET data: high-risk ET patients who started ropeginterferon earlier had 76.9% progression-free survival at 24 months, compared to 43.1% for those whose treatment was delayed.
https://pvreporter.com/surpass-et-earlier-ropeginterferon-shows-2-year-benefit/
Seven years. Two medications. Five failed doctors.
When I was diagnosed with polycythemia vera in 2009, no one told me remission was possible. The only treatment I was offered, phlebotomy, guaranteed it wouldn't be.
Today my blood counts are normal. The molecular markers driving my PV are undetectable.
I just published the most personal article I've ever written. It covers how I got here, what it cost, the moment at ASH 2015 that changed everything, and what I want every PV patient to know.
This isn't a typical outcome. I won't pretend it is. But most patients are never told deeper responses are even on the table, and they deserve to know.
Read the full story: https://pvreporter.com/polycythemia-vera-molecular-remission/